In her 2019 Netflix standup special “Not Normal,” comedian Wanda Sykes jokes that if men got hot flashes, “they would blow the sun up.” “There’s no way in the world ...

Moderna’s COVID-19 vaccine production partner Recipharm unveiled not one, but two acquisitions on Friday amid an expansion sprint that’s been ongoing since last summe...

Animal health giant Elanco completed the sale of a pair of manufacturing facilities to TriRx Pharmaceutical Services, a Connecticut-based CDMO. Financial terms of th...

CDMO Skyepharma inked a deal to build what is being touted as the largest microbiome production facility in France for the clinical-stage biotech MaaT Pharma. The fa...

Eli Lilly has been talking up a “disruptive” pricing strategy for its Innovent Biologics-partnered PD-1 inhibitor Tyvyt in the U.S. Now, we have an idea of what the c...

Virpax Pharmaceuticals has brought its nasal spray for acute and chronic pain through an early test. With the National Institutes of Health (NIH) footing the bill, Vi...

Merck & Co. and Eisai’s Lenvima has posted its share of positive data readouts over the years, but bladder cancer remains a tough nut to crack. In newly released ...

In 2017 and 2020, Zejula snagged broad FDA labels for ovarian cancer patients who responded well to chemotherapy. But in prostate cancer, the PARP inhibitor appears t...

The risk of heart-related issues accompanying the use of JAK inhibitors has brought the entire drug class under scrutiny. Last September, the FDA said it will require...

Since snapping up rare disease biopharma Shire for $62 billion back in 2019, Takeda has been boosting its marketing might on conditions not in the mainstream. As we h...